C2N Diagnostics Secures $10 Million from Samsung to Advance Diagnostic Solutions for Brain Health

C2N Diagnostics, a St. Louis, MO-based leader in advanced diagnostic solutions for brain health, has announced a $10 million investment from Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. This strategic funding will support C2N’s efforts to expand its clinical laboratory services and innovate next-generation diagnostic tests for Alzheimer’s disease and related dementias.

Early and accurate diagnosis is critical given the personal, financial, and societal impacts of Alzheimer’s disease. C2N’s best-in-class blood biomarker testing technologies, such as the PrecivityAD2™ test, aim to address this need by providing highly accurate diagnostic tools accessible to patients worldwide.

“The investment into C2N Diagnostics reflects Samsung’s commitment to future growth in the life sciences sector through intelligent analytics and unique diagnostic technologies,” said Jaywoo Kim, Executive Vice President of Samsung C&T Corporation. “We are confident that C2N will further solidify its leading position in the industry by serving global biopharma customers and medical providers with its innovative blood biomarker testing portfolio.”

Dr. Joel Braunstein, CEO of C2N Diagnostics, added, “Samsung’s investment underscores the value of our advanced diagnostic solutions. This partnership will enable us to strengthen our capabilities, expand our commercial scale, and develop next-generation tests that improve patients’ lives.”

C2N’s PrecivityAD2™ blood test algorithm has demonstrated over 90% diagnostic accuracy in clinical studies, as published in The Journal of the American Medical Association (JAMA). With over 50,000 Precivity™ analytes reported and more than 150 global collaborations, C2N is advancing Alzheimer’s research and expanding its biomarker pipeline to include tau pathology, Parkinson’s disease, and decentralized mass spectrometry testing.

This investment marks a significant step forward in C2N’s mission to bring clarity and innovation to brain health diagnostics, ensuring patients worldwide have access to cutting-edge diagnostic solutions.